EMC Insurance Companies is one of the largestproperty and casualty entities in Iowa and among the top

EMC Insurance Companies is one of the largestproperty and casualty entities in Iowa and among the top 60 insurance entitiesnationwide based on premium volume For more information, visit our website. The Private Securities Litigation Reform Act of 1995 provides issuers theopportunity to make cautionary statements regarding forward-looking statements.Accordingly, any forward-looking statement contained in this report is based onmanagement`s current beliefs, assumptions and expectations of the Company`sfuture performance, taking into account all information currently available tomanagement. These beliefs, assumptions and expectations can change as the resultof many possible events or factors, not all of which are known to management. Ifa change occurs, the Company`s business, financial condition, liquidity, resultsof operations, plans and objectives may vary materially from those expressed inthe forward-looking statements. The risks and uncertainties that may affect theactual results of the Company include, but are not limited to, the following:catastrophic events and the occurrence of significant severe weather conditions;the adequacy of loss and settlement expense reserves; state and federallegislation and regulations; changes in the property and casualty insuranceindustry, interest rates and the performance of financial markets and thegeneral economy; rating agency actions and other risks and uncertaintiesinherent to the Company`s business, including those discussed under the heading”Risk Factors” in the Company`s annual report on Form 10-K. Management intendsto identify forward-looking statements when using the words “believe”, “expect”,”anticipate”, “estimate”, “project” or similar expressions. Undue relianceshould not be placed on these forward-looking statements.

¹The Company uses a non-GAAP financial measure called “operating income” thatmanagement believes is useful to investors because it illustrates theperformance of our normal, ongoing operations, which is important inunderstanding and evaluating our financial condition and results of operations.While this measure is consistent with measures utilized by investors to evaluateperformance, it is not a substitute for the U.S GAAP financial measure of netincome. Therefore, the Company has provided the following reconciliation of thisnon-GAAP financial measure to the U.S. GAAP financial measure of net income.Management also uses non-GAAP financial measures for goal setting, determiningemployee and senior management awards and compensation, and evaluatingperformance. MOUNT PLEASANT, S.C.–(Business Wire)–Revolutions Medical Corporation (OTCBB: RMCP – News) recently signed a worldwideexclusive license with Strategic Product Development (SPD) for an image guidednavigation system that incorporates high accuracy breast biopsies system (BBS)to conventional mammography systems which number more than 50,000 globally.

Thistechnology has already received 510K clearance by the FDA. BBS facilitatesaccurate and fast non-palpable lesions and micro calcification localization inthe treatment of breast cancer. It is low-cost, standalone stereotacticimage-based system which uses data from a pair of mammograms to enableradiologists to accurately position a localization needle or biopsy tool at thelocation of suspicious abnormalities in the patient`s breast. RevolutionsMedical believes that the BBS will offer significant advantages for thelocalization and biopsy of breast abnormalities.

The system can also be modifiedto leverage existing popular biopsy tools. The technology can be used to providea technology platform for future development including multi-modal breastimaging for the image fusion of MRI and X-Ray images. This represents anotherstep in RevMed`s mission statement “To make health care safer and less expensiveby developing and marketing new products and tools to the medical industry.” TheBBS will be modified to use Rev Med`s proprietary safety syringe technology aswell. Approximately 4 million diagnostic procedures are performed annually worldwideto evaluate abnormalities detected during mammography screening. RevMed believesthat this technology has the potential to be deployed in the vast majority ofmore than 50,000 mammography machines that are currently in use worldwide,including more than 15,000 in the U.S This market also represents $400M peryear in disposables.